abrdn Life Sciences Investors (NYSE:HQL) Sees Large Increase in Short Interest

abrdn Life Sciences Investors (NYSE:HQL) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 192,658 shares, an increase of 70.8% from the September 30th total of 112,812 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average trading volume of 139,589 shares, the days-to-cover ratio is currently 1.4 days.

abrdn Life Sciences Investors Stock Performance

HQL opened at $18.10 on Wednesday. The firm’s fifty day moving average is $18.93 and its 200 day moving average is $18.24. abrdn Life Sciences Investors has a fifty-two week low of $15.66 and a fifty-two week high of $22.67.

abrdn Life Sciences Investors Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Monday, August 24th were paid a $0.62 dividend. The ex-dividend date was Monday, August 24th. This represents a $2.48 annualized dividend and a yield of 13.7%.

Hedge Funds Weigh In On abrdn Life Sciences Investors

A number of large investors have recently bought and sold shares of HQL. Flagship Harbor Advisors LLC raised its holdings in shares of abrdn Life Sciences Investors by 4.1% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 417,366 shares of the company’s stock valued at $7,805,000 after purchasing an additional 16,601 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of abrdn Life Sciences Investors by 57.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company’s stock valued at $5,898,000 after acquiring an additional 132,098 shares during the period. Formidable Asset Management LLC lifted its stake in abrdn Life Sciences Investors by 0.7% in the 3rd quarter. Formidable Asset Management LLC now owns 166,324 shares of the company’s stock valued at $3,328,000 after buying an additional 1,081 shares in the last quarter. 180 Wealth Advisors LLC grew its holdings in shares of abrdn Life Sciences Investors by 2.2% in the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after purchasing an additional 3,271 shares during the period. Finally, Royal Bank of Canada lifted its stake in shares of abrdn Life Sciences Investors by 16.5% in the 1st quarter. Royal Bank of Canada now owns 121,240 shares of the company’s stock valued at $1,972,000 after purchasing an additional 17,152 shares during the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors is a publicly traded closed-end investment company listed on the New York Stock Exchange under the symbol HQL. The fund seeks long-term capital appreciation by investing in companies involved in the life sciences industry.

Its portfolio may include businesses across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related fields. The fund can invest in both publicly traded and privately held companies, providing shareholders with diversified exposure to innovative healthcare and life sciences businesses.

The fund was formerly known as Tekla Life Sciences Investors and adopted the abrdn name following the integration of Tekla’s investment management activities into abrdn.